Entrada Therapeutics
Applies a cyclic-peptide delivery platform to exon-skipping therapies for Duchenne muscular dystrophy and myotonic dystrophy.
Something off on this page? Send us feedback.
Profile
Develops therapies built on a cyclic-peptide delivery platform that shuttles oligonucleotides into cells, applying it first to exon-skipping treatments for Duchenne muscular dystrophy and, through a partnership with Vertex Pharmaceuticals, to myotonic dystrophy type 1; no therapy has reached the market and collaboration payments remain the primary revenue source.
Uses a cyclic-peptide delivery platform, the Endosomal Escape Vehicle, to carry oligonucleotides past the cell membrane and out of the endosome into the cytosol, reaching disease targets inside cells rather than on the surface.
The lead franchise applies that platform to exon-skipping oligonucleotides for Duchenne muscular dystrophy, with candidates targeting exons 44, 45, 50 and 51; the exon-44 program is furthest along, in clinical trials outside and inside the US.
A separate program for myotonic dystrophy type 1 advances through a partnership with Vertex Pharmaceuticals, which funds and runs an early-stage global trial and has been the primary source of revenue to date.
A multiyear US clinical hold on the exon-44 program, lifted in 2025 after supporting data gathered outside the country, delayed domestic trials; no therapy has yet reached the market.
Company facts
Key statistics
Year to date −30.5% · Average volume (30d) 359.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Roth Capital | Reiterate | Buy | $10 | $11 | |
| Jun 8, 2026 | Guggenheim | Reiterate | Buy | $20 | $17 | |
| May 8, 2026 | Roth Capital | Target | $13 | $10 | ||
| May 8, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral | ||
| Feb 10, 2026 | Guggenheim | Target | $20 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.97 | −$1.01 | −3.7% | $2.3M | $898.0K | −61.4% | −2.49% |
| May 7, 2026Q1 FY26 | −$1.06 | −$0.95 | +10.4% | $2.9M | $875.0K | −70.0% | −0.15% |
| Feb 26, 2026Q4 FY25 | −$1.32 | −$0.94 | +28.8% | $7.4M | $1.3M | −82.5% | −6.72% |
| Nov 6, 2025Q3 FY25 | −$1.04 | −$1.06 | −1.9% | $8.5M | $1.6M | −81.0% | −0.58% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $20.6M | $2.0M | $1.6M | $1.3M | $875.0K | $898.0K | |
| Gross profit | $20.6M | $2.0M | −$36.7M | $413.0K | $70.0K | $898.0K | |
| Operating income | −$21.8M | −$46.8M | −$47.1M | −$42.2M | −$42.3M | −$45.0M | |
| Net income | −$17.3M | −$43.1M | −$44.1M | −$39.2M | −$39.7M | −$42.8M | |
| Diluted EPS | −$0.42 | −$1.04 | −$1.06 | −$0.95 | −$0.95 | −$1.01 | |
| Gross margin | 100.0% | 100.0% | -2,276.8% | 31.8% | 8.0% | 100.0% | |
| Operating margin | -106.0% | -2,402.5% | -2,915.2% | -3,249.3% | -4,834.6% | -5,007.0% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $129.0M · FY24 $210.8M · FY25 $25.4M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $223.0M · Total debt $48.5M · Total assets $298.9M · Shareholders' equity $233.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 38.82M · Float 22.21M · 57.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 5.07M | 13.07% | 13F | Aug 14, 2026 |
| MPM BioVentures 2014, L.P. · 10 percent owner | 4.32M | 11.12% | Form 4 | Aug 26, 2026 |
| 5Am Venture Management, LLC | 4.06M | 10.45% | 13F | Aug 14, 2026 |
| 5AM Ventures V, L.P. · 10 percent owner | 3.88M | 9.99% | Form 4 | Aug 10, 2026 |
| Kush Parmar · director | 2.69M | 6.93% | Form 4 | Aug 10, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | BioVentures 2014 L.P. MPM | 10 percent owner | −14,569 | $7.06 |
| Aug 25, 2026 | BioVentures 2014 L.P. MPM | 10 percent owner | −26,522 | $7.54 |
| Aug 24, 2026 | BioVentures 2014 L.P. MPM | 10 percent owner | −21,623 | $7.34 |
| Aug 26, 2026 | Bioventures 2018 L.p. Mpm | 10 percent owner | −14,569 | $7.06 |
| Aug 25, 2026 | Bioventures 2018 L.p. Mpm | 10 percent owner | −26,522 | $7.54 |
Peers
- Sarepta Therapeutics
Head-to-head in DMD exon-skipping with approved products across exons 45/51.
- Dyne Therapeutics
Antibody-fragment delivery platform racing ahead on exon 51 and DM1.
- PepGen
Peptide-conjugate delivery rival, now concentrated in DM1 after exiting DMD.
- Wave Life Sciences
Exon-53 DMD program on a rival stereopure oligonucleotide platform.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Entrada Therapeutics | $7.00 | +0.29% | $271.7M | — | — | 58.0 | −54.0% |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| PepGen | $3.08 | −0.16% | $213.0M | — | — | — | — |
| Wave Life Sciences | $5.09 | +1.07% | $993.1M | — | — | 15.2 | −73.9% |
| Median | — | 26.3 | 8.2 | −54.1% |